USD 6.81
↓ -0.04 (-0.58%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ANGO | -0.6 | -5.2 | 7.6 | -8.7 | 7.1 | -1.9 | -76.6 | -55.9 | -59.6 | -45.5 |
| S&P 500 | -1.3 | -1.8 | 1.0 | 5.9 | 10.6 | 30.4 | 25.4 | 88.1 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ANGO |
| name | AngioDynamics, Inc. |
| price | 6.81 |
| changes percentage | -0.5839 |
| change | -0.04 |
| day low | 6.72 |
| day high | 6.91 |
| year high | 8.25 |
| year low | 5.26 |
| market cap | 276719583 |
| price avg 50 | 7.011 |
| price avg 200 | 6.5188 |
| exchange | NASDAQ |
| volume | 470989 |
| avg volume | 486046 |
| open | 6.88 |
| previous close | 6.85 |
| eps | -6.05 |
| pe | -1.13 |
| earnings announcement | 2025-01-02T12:00:00.000+0000 |
| shares outstanding | 40634300 |
| timestamp | 2024-11-15 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001275187 | |||
| revenue | 303914000 | 338752000 | -10.28 |
| gross profit | 154698000 | 174246000 | -11.22 |
| gross profit ratio | 0.51 | 0.51 | -1.04 |
| research and development expenses | 31512000 | 29883000 | 5.45 |
| operating expenses | 252416000 | 192925000 | 30.84 |
| interest income | 0 | 2702000 | -100.00 |
| interest expense | 0 | 2702000 | -100.00 |
| ebitda | -14292000 | 12194000 | -217.21 |
| ebitdaratio | -0.05 | 0.03 | -236.86 |
| operating income | -97718000 | -19233000 | -408.07 |
| operating income ratio | -0.32 | -0.06 | -466.32 |
| net income | -184349000 | -52442000 | -251.53 |
| net income ratio | -0.61 | -0.15 | -291.83 |
| eps | -4.59 | -1.33 | -245.11 |
Revenue Growth: revenue decreased to 304 million in 2024 from 339 million in 2023 representing a change of -10.28%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 155 million in 2024 from 174 million in 2023 representing a change of -11.22%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 252 million in 2024 from 193 million in 2023 representing a change of 30.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -14 million in 2024 from 12 million in 2023 representing a change of -217.21%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -184 million in 2024 from -52 million in 2023 representing a change of -251.53%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -4.59 in 2024 from -4.59 in 2023 representing a change of -245.11%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 32 million in 2024 from 30 million in 2023 representing a change of 5.45%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to -98 million in 2024 from -19 million in 2023 representing a change of -408.07%. The increase in operating income indicates better operational performance and increased profitability.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001275187 | |||
| revenue | 67491000 | 70980000 | -4.92 |
| gross profit | 36724000 | 35941000 | 2.18 |
| gross profit ratio | 0.54 | 0.51 | 7.46 |
| research and development expenses | 6285000 | 6724000 | -6.53 |
| operating expenses | 45435000 | 41746000 | 8.84 |
| interest income | 606000 | 0 | NaN |
| interest expense | 0 | 567000 | -100.00 |
| ebitda | -1926000 | -7324000 | 73.70 |
| ebitdaratio | -0.03 | 0.01 | -300.15 |
| operating income | -13098000 | -5805000 | -125.63 |
| operating income ratio | -0.19 | -0.08 | -137.30 |
| net income | -12798000 | -13449000 | 4.84 |
| net income ratio | -0.19 | -0.19 | -0.08 |
| eps | -0.31 | -0.33 | 6.06 |
Revenue Growth: revenue decreased to 67 million in 2025Q1 from 71 million in 2024Q4 representing a change of -4.92%. This indicates a sales shrinking, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 6 million in 2025Q1 from 7 million in 2024Q4 representing a change of -6.53%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 45 million in 2025Q1 from 42 million in 2024Q4 representing a change of 8.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -2 million in 2025Q1 from -7 million in 2024Q4 representing a change of 73.7%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -13 million in 2025Q1 from -6 million in 2024Q4 representing a change of -125.63%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -13 million in 2025Q1 from -13 million in 2024Q4 representing a change of 4.84%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to 37 million in 2025Q1 from 36 million in 2024Q4 representing a change of 2.18%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -0.31 in 2025Q1 from -0.31 in 2024Q4 representing a change of 6.06%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001275187 | |||
| total assets | 317671000 | 532637000 | -40.36 |
| total liabilities | 112085000 | 154341000 | -27.38 |
| total equity | 205586000 | 378296000 | -45.65 |
| cash and cash equivalents | 76056000 | 44620000 | 70.45 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | -12813000 | 100.00 |
| total current assets | 193253000 | 163542000 | 18.17 |
| total non current assets | 124418000 | 369095000 | -66.29 |
| total current liabilities | 91155000 | 83825000 | 8.74 |
| total non current liabilities | 20930000 | 70516000 | -70.32 |
| common stock | 385000 | 382000 | 0.79 |
| retained earnings | -395204000 | -210855000 | -87.43 |
| total debt | 5914000 | 49818000 | -88.13 |
Total Assets: Total Assets decreased to 318 million in 2024 from 533 million in 2023 representing a change of -40.36%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 206 million in 2024 from 378 million in 2023 representing a change of -45.65%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 91 million in 2024 from 84 million in 2023 representing a change of 8.74%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -395 million in 2024 from -211 million in 2023 representing a change of -87.43%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 112 million in 2024 from 154 million in 2023 representing a change of -27.38%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 76 million in 2024 from 45 million in 2023 representing a change of 70.45%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 193 million in 2024 from 164 million in 2023 representing a change of 18.17%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024 from 0 in 2023 representing a change of 0.79%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 6 million in 2024 from 50 million in 2023 representing a change of -88.13%. This indicates a reduction in overall debt burden.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001275187 | |||
| total assets | 293628000 | 317671000 | -7.57 |
| total liabilities | 97046000 | 112085000 | -13.42 |
| total equity | 196582000 | 205586000 | -4.38 |
| cash and cash equivalents | 55005000 | 76056000 | -27.68 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | -4852000 | 100.00 |
| total current assets | 172594000 | 193253000 | -10.69 |
| total non current assets | 121034000 | 124418000 | -2.72 |
| total current liabilities | 76699000 | 91155000 | -15.86 |
| total non current liabilities | 20347000 | 20929999 | -2.79 |
| common stock | 386000 | 385000 | 0.26 |
| retained earnings | -408002000 | -395204000 | -3.24 |
| total debt | 4804000 | 5914000 | -18.77 |
Total Assets: Total Assets decreased to 294 million in 2025Q1 from 318 million in 2024Q4 representing a change of -7.57%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 197 million in 2025Q1 from 206 million in 2024Q4 representing a change of -4.38%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 55 million in 2025Q1 from 76 million in 2024Q4 representing a change of -27.68%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 173 million in 2025Q1 from 193 million in 2024Q4 representing a change of -10.69%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -408 million in 2025Q1 from -395 million in 2024Q4 representing a change of -3.24%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 97 million in 2025Q1 from 112 million in 2024Q4 representing a change of -13.42%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 77 million in 2025Q1 from 91 million in 2024Q4 representing a change of -15.86%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2025Q1 from 0 in 2024Q4 representing a change of 0.26%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 5 million in 2025Q1 from 6 million in 2024Q4 representing a change of -18.77%. This indicates a reduction in overall debt burden.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001275187 | |||
| net change in cash | 31436000 | 15795000 | 99.03 |
| operating cash flow | -28158000 | 78000 | -36200.00 |
| free cash flow | -33926000 | -4274000 | -693.78 |
| capital expenditure | -5768000 | -4352000 | -32.54 |
| depreciation and amortization | 27712000 | 30873000 | -10.24 |
| deferred income tax | -7968000 | -2310000 | -244.94 |
| stock based compensation | 10529000 | 11158000 | -5.64 |
| accounts payables | 27531000 | 2139000 | 1187.10 |
| inventory | -9410000 | -8198000 | -14.78 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -2518000 | -4352000 | 42.14 |
| net cash used for investing activites | 123717000 | -9746000 | 1369.41 |
| debt repayment | -50000000 | 25000000 | -300.00 |
| common stock issued | 0 | 1171000 | -100.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -64248000 | 25420000 | -352.75 |
| cash at end of period | 76056000 | 44620000 | 70.45 |
| accounts receivables | 7894000 | -1299000 | 707.70 |
| cash at beginning of period | 44620000 | 28825000 | 54.80 |
Net Change in Cash: Net Change in Cash increased to 31 million in 2024 from 16 million in 2023 representing a change of 99.03%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -6 million in 2024 from -4 million in 2023 representing a change of -32.54%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 11 million in 2024 from 11 million in 2023 representing a change of -5.64%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow decreased to -28 million in 2024 from 0 million in 2023 representing a change of -36200.0%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -34 million in 2024 from -4 million in 2023 representing a change of -693.78%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 28 million in 2024 from 2 million in 2023 representing a change of 1187.1%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 8 in 2024 from -1 million in 2023 representing a change of 707.7%. This suggests that the company is less capable of collecting payments from its customers.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001275187 | |||
| operating cash flow | -18253000 | 5001000 | -464.99 |
| free cash flow | -19345000 | -580000 | -3235.34 |
| capital expenditure | -1092000 | -5581000 | 80.43 |
| depreciation and amortization | 6785000 | 6817000 | -0.47 |
| deferred income tax | -339000 | -825000 | 58.91 |
| stock based compensation | 3205000 | 1896000 | 69.04 |
| accounts receivables | 3784000 | 5549000 | -31.81 |
| accounts payables | -14982000 | 10787000 | -238.89 |
| inventory | -4053000 | -2585000 | -56.79 |
| acquisitions net | 0 | -134500000 | 100.00 |
| investments in property plant and equipment | -1092000 | -5581000 | 80.43 |
| net cash used for investing activites | -2405000 | -2336000 | -2.95 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | -752000 | 100.00 |
| common stock repurchased | -552000 | 352000 | -256.82 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -509000 | -5000000 | 89.82 |
| net change in cash | -21051000 | -2395000 | -778.96 |
| cash at end of period | 55005000 | 76056000 | -27.68 |
| cash at beginning of period | 76056000 | 78451000 | -3.05 |
Net Change in Cash: Net Change in Cash decreased to -21 million in 2025Q1 from -2 million in 2024Q4 representing a change of -778.96%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -18 million in 2025Q1 from 5 million in 2024Q4 representing a change of -464.99%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -19 million in 2025Q1 from -1 million in 2024Q4 representing a change of -3235.34%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -1 million in 2025Q1 from -6 million in 2024Q4 representing a change of 80.43%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2025Q1 from -1 million in 2024Q4 representing a change of 58.91%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 3 million in 2025Q1 from 2 million in 2024Q4 representing a change of 69.04%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 15 million in 2025Q1 from 11 million in 2024Q4 representing a change of -238.89%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 4 million in 2025Q1 from 6 million in 2024Q4 representing a change of -31.81%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q1 2025 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-05-31 | 2023-05-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 7.56 | 8.58 | -11.85 |
| net income per share | -4.59 | -1.33 | -245.40 |
| operating cash flow per share | -0.7 | 0.0 | -35570.59 |
| free cash flow per share | -0.84 | -0.11 | -679.94 |
| cash per share | 1.89 | 1.13 | 67.48 |
| book value per share | 5.12 | 9.58 | -46.60 |
| tangible book value per share | 3.19 | 2.73 | 16.73 |
| shareholders equity per share | 5.12 | 9.58 | -46.60 |
| interest debt per share | 0 | 1.33 | -100.00 |
| market cap | 253541636.75 | 373484271.82 | -32.11 |
| enterprise value | 183399636.75 | 378682271.82 | -51.57 |
| pe ratio | -1.38 | -7.12 | 80.69 |
| price to sales ratio | 0.83 | 1.1 | -24.33 |
| pocfratio | -9.0 | 4788.26 | -100.19 |
| pfcf ratio | -7.47 | -87.39 | 91.45 |
| pb ratio | 1.23 | 0.99 | 24.92 |
| ptb ratio | 1.23 | 0.99 | 24.92 |
| ev to sales | 0.6 | 1.12 | -46.02 |
| enterprise value over ebitda | -12.83 | 31.05 | -141.32 |
| ev to operating cash flow | -6.51 | 4854.9 | -100.13 |
| ev to free cash flow | -5.41 | -88.6 | 93.90 |
| earnings yield | -0.73 | -0.14 | -417.83 |
| free cash flow yield | -0.13 | -0.01 | -1069.29 |
| debt to equity | 0 | 0.13 | -100.00 |
| debt to assets | 0 | 0.09 | -100.00 |
| net debt to ebitda | 4.91 | 0.43 | 1051.32 |
| current ratio | 2.12 | 1.95 | 8.67 |
| interest coverage | 0 | -7.12 | 100.00 |
| income quality | 0.15 | -0.0 | 10369.41 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.14 | 0.12 | 14.70 |
| research and ddevelopement to revenue | 0.1 | 0.09 | 17.54 |
| intangibles to total assets | 0.24 | 0.51 | -52.01 |
| capex to operating cash flow | -0.2 | 55.79 | -100.37 |
| capex to revenue | 0.02 | 0.01 | 47.73 |
| capex to depreciation | 0.21 | 0.14 | 47.65 |
| stock based compensation to revenue | 0.03 | 0.03 | 5.18 |
| graham number | 22.98 | 16.92 | 35.81 |
| roic | -0.46 | -0.04 | -956.50 |
| return on tangible assets | -0.77 | -0.2 | -283.67 |
| graham net net | 0.67 | -1.07 | 162.48 |
| working capital | 102098000 | 79717000 | 28.08 |
| tangible asset value | 128203000 | 107914000 | 18.80 |
| net current asset value | 81168000 | 9201000 | 782.16 |
| invested capital | 220951000 | 394483000 | -43.99 |
| average receivables | 48218000 | 52565000 | -8.27 |
| average payables | 39098000 | 34246000 | 14.17 |
| average inventory | 57970500 | 53358500 | 8.64 |
| days sales outstanding | 52.38 | 56.92 | -7.98 |
| days payables outstanding | 92.34 | 89.74 | 2.90 |
| days of inventory on hand | 148.27 | 122.75 | 20.79 |
| receivables turnover | 6.97 | 6.41 | 8.68 |
| payables turnover | 3.95 | 4.07 | -2.82 |
| inventory turnover | 2.46 | 2.97 | -17.21 |
| roe | -0.9 | -0.14 | -546.84 |
| capex per share | 0.14 | 0.11 | 30.23 |
ROE: Return on Equity (ROE) decreased to -0.90 on 2024-05-31 from -0.14 on 2023-05-31, representing a change of -546.84%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.38 on 2024-05-31 from -7.12 on 2023-05-31, representing a change of 80.69%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.12 on 2024-05-31 from 1.95 on 2023-05-31, representing a change of 8.67%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-05-31 from 0.13 on 2023-05-31, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-08-31 Q1 | 2024-05-31 Q4 | Q/Q change % | |
|---|---|---|---|
| ANGO | |||
| calendar year | 2025 | 2024 | NaN |
| revenue per share | 1.66 | 1.76 | -5.44 |
| net income per share | -0.31 | -0.33 | 5.37 |
| operating cash flow per share | -0.45 | 0.12 | -462.96 |
| free cash flow per share | -0.48 | -0.01 | -3216.80 |
| cash per share | 1.35 | 1.88 | -28.08 |
| book value per share | 4.84 | 5.09 | -4.91 |
| tangible book value per share | 2.97 | 3.17 | -6.29 |
| shareholders equity per share | 4.84 | 5.09 | -4.91 |
| interest debt per share | 0 | 0.06 | -100.00 |
| market cap | 303271380 | 255094370.0 | 18.89 |
| enterprise value | 253070380 | 184952370.0 | 36.83 |
| pe ratio | -5.92 | -4.74 | -24.93 |
| price to sales ratio | 4.49 | 3.59 | 25.03 |
| pocfratio | -16.61 | 51.01 | -132.57 |
| pfcf ratio | -15.68 | -439.82 | 96.44 |
| pb ratio | 1.54 | 1.24 | 24.33 |
| ptb ratio | 1.54 | 1.24 | 24.33 |
| ev to sales | 3.75 | 2.61 | 43.90 |
| enterprise value over ebitda | -131.4 | -25.25 | -420.32 |
| ev to operating cash flow | -13.86 | 36.98 | -137.49 |
| ev to free cash flow | -13.08 | -318.88 | 95.90 |
| earnings yield | -0.04 | -0.05 | 19.96 |
| free cash flow yield | -0.06 | -0.0 | -2705.50 |
| debt to equity | 0 | 0.01 | -100.00 |
| debt to assets | 0 | 0.01 | -100.00 |
| net debt to ebitda | 26.06 | 9.58 | 172.16 |
| current ratio | 2.25 | 2.12 | 6.14 |
| interest coverage | 0 | -10.24 | 100.00 |
| income quality | 1.43 | -0.37 | 483.55 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.16 | 0.15 | 10.55 |
| research and ddevelopement to revenue | 0.09 | 0.09 | -1.70 |
| intangibles to total assets | 0.26 | 0.24 | 5.94 |
| capex to operating cash flow | -0.06 | 1.12 | -105.36 |
| capex to revenue | 0.02 | 0.08 | -79.42 |
| capex to depreciation | 0.16 | 0.82 | -80.34 |
| stock based compensation to revenue | 0.05 | 0.03 | 77.78 |
| graham number | 5.85 | 6.17 | -5.14 |
| roic | -0.07 | -0.03 | -153.12 |
| return on tangible assets | -0.06 | -0.06 | -4.96 |
| graham net net | 0.49 | 0.67 | -26.37 |
| working capital | 95895000 | 102098000 | -6.08 |
| tangible asset value | 120808000 | 128203000 | -5.77 |
| net current asset value | 75548000 | 81168000 | -6.92 |
| invested capital | 206046000 | 220951000 | -6.75 |
| average receivables | 41586500 | 46542500 | -10.65 |
| average payables | 34511500 | 36451500 | -5.32 |
| average inventory | 62658000 | 59342000 | 5.59 |
| days sales outstanding | 52.76 | 55.3 | -4.59 |
| days payables outstanding | 91.48 | 96.97 | -5.66 |
| days of inventory on hand | 189.26 | 155.7 | 21.56 |
| receivables turnover | 1.71 | 1.63 | 4.81 |
| payables turnover | 0.98 | 0.93 | 6.00 |
| inventory turnover | 0.48 | 0.58 | -17.73 |
| roe | -0.07 | -0.07 | 0.48 |
| capex per share | 0.03 | 0.14 | -80.54 |
ROE: Return on Equity (ROE) decreased to -0.07 on 2024-08-31 Q1 from -0.07 on 2024-05-31 Q4, representing a change of 0.48%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -5.92 on 2024-08-31 Q1 from -4.74 on 2024-05-31 Q4, representing a change of -24.93%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.25 on 2024-08-31 Q1 from 2.12 on 2024-05-31 Q4, representing a change of 6.14%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-08-31 Q1 from 0.01 on 2024-05-31 Q4, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -4.69 which is lower than current price 6.81, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-01 10:56:08
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sentiment: Negative
Publish Date: 2024-10-29 11:46:09
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
Sentiment: Neutral
Publish Date: 2024-10-23 13:36:09
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Sentiment: Positive
Publish Date: 2024-10-08 10:35:31
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sentiment: Positive
Publish Date: 2024-10-04 12:47:24
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Sentiment: Negative
Publish Date: 2024-10-03 11:40:15
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Sentiment: Negative
Publish Date: 2024-10-03 11:23:22
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
Sentiment: Negative
Publish Date: 2024-10-03 10:02:05
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
Sentiment: Negative
Publish Date: 2024-10-03 08:41:07
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-03 06:30:00
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million.
Sentiment: Positive
Publish Date: 2024-10-03 03:37:09
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
Sentiment: Positive
Publish Date: 2024-09-30 08:05:22
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
Sentiment: Positive
Publish Date: 2024-09-23 10:36:15
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
Sentiment: Positive
Publish Date: 2024-09-19 16:40:00
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for Treatment of Acut.
Sentiment: Positive
Publish Date: 2024-09-19 08:00:00
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to.
Sentiment: Positive
Publish Date: 2024-09-13 08:16:07
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
Sentiment: Positive
Publish Date: 2024-09-09 08:40:16
DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.
Sentiment: Positive
Publish Date: 2024-09-04 12:25:18
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
Sentiment: Positive
Publish Date: 2024-08-27 13:01:51
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
